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Purpose: The present study investigated the effect of mitomycin C (MMC) on cell viability, apoptosis, and transforming
growth factor beta-induced protein (TGFBIp) expression in cultured normal corneal fibroblasts and heterozygote or
homozygote granular corneal dystrophy type II (GCD II) corneal fibroblasts.
Methods: Keratocytes were obtained from normal cornea or from heterozygote or homozygote GCD II patients after
lamellar or penetrating keratoplasty. To measure cell viability, corneal fibroblasts were incubated with 0.02% MMC for
3 h, 6 h, and 24 h or with 0%, 0.01%, 0.02%, and 0.04% MMC for 24 h and then tested using lactate dehydrogenase (LDH)
and 3-[4,5-demethylthiazol-2,5-diphenyl-2H-tetrazolium bromide] (MTT) assays. To measure apoptosis, cells were
analyzed by FACS analysis and annexin V staining. Bcl-xL, Bax, and TGFBI mRNA expression was measured using
reverse transcription polymerase chain reaction (RT–PCR) assays. Cellular and media levels of TGFBIp protein were
measured by immunoblotting.
Results: MTT and LDH assays showed that MMC reduced cell viability in all three cell types in a dose-dependent and
time-dependent manner (p<0.05). FACS analysis and annexin V staining showed that MMC caused apoptosis with GCD
II homozygote cells being most affected. RT–PCR analysis showed that MMC decreased Bcl-xL mRNA expression and
increased Bax mRNA expression in all cell types. RT–PCR and immunoblotting analysis showed that MMC reduced
TGFBI mRNA levels and cellular and media TGFBIp protein levels in all cell types.
Conclusions: MMC induced apoptosis, and the effects of MMC were greatest in GCD II homozygote cells. MMC also
reduced the production of TGFBIp in all three types of corneal fibroblasts. These findings may explain the additional
therapeutic effect of MMC in GCD II patients.
Abnormal deposition of extracellular matrix proteins is a
key event related to the loss of corneal transparency in corneal
dystrophies. The extracellular transforming growth factor
beta-induced protein gene (TGFBI), which is located on 5q31,
has been studied in relation to corneal dystrophies and several
mutations have been found [1-4]. The gene encodes a 683
amino acid protein, which has been given several names
including keratoepithelin [5], βigh3 protein [6], and TGFBIp.
Antibodies directed against TGFBIp were found to react to
corneal deposits in TGFBI-related corneal dystrophies [7].
While the mechanism underlying pathological deposition of
TGFBI remains to be fully understood, the main component
of the deposit is TGFBIp derived from mutant TGFBI.
Granular corneal dystrophy type II (GCD II; Avellino
corneal dystrophy) represents a mixed-type corneal dystrophy
resulting from an R124H mutation of TGFBIp, which is
activated by TGF-β [8,9]. GCD II is more common in Asia
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than GCD type I, which is associated with an R555W mutation
[10,11].
While phototherapeutic keratectomy (PTK) is the
recommended treatment for granular corneal dystrophy, a
major problem has been recurrence after treatment [12].
Similarly, penetrating keratoplasty can be used to replace the
opaque cornea, but deposits can recur along the suture tract
and even on the grafted donor cornea within several years of
surgery [13]. Recently, refractive surgery has become a more
commonly performed procedure. As such, reportedly severe
aggravation of corneal deposits after refractive surgical
procedures has made GCD II a cause for concern [14].
Mitomycin C (MMC) is widely used in the ophthalmic
field due to its antiproliferative activity, which results from an
inhibition of DNA synthesis secondary to alkylation [15-17].
The use of MMC to prevent subepithelial opacity after
refractive procedures has resulted in promising outcomes via
apoptosis of keratocytes [18,19]. Keratocyte apoptosis is the
earliest stromal change observable after epithelial injury and
is considered an initiator of the corneal wound healing
response. As such, the inhibition of keratocyte apoptosis could
result in diminished keratocyte activation. Therefore,
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regulating keratocyte apoptosis may be an effective way to
control the response to wounding [20].
We have previously reported that the intraoperative use
of topical 0.02% MMC in conjunction with PTK prevented or
delayed GCD II recurrence [21]. Despite the clinical use of
MMC, there are few supporting in vitro studies that have
investigated its mechanism of action. The present study
examined the effect of MMC on cultured corneal fibroblasts
derived from normal, heterozygote GCD II, and homozygote
GCD II individuals. The study examined the effect of MMC
on cell viability, apoptosis, and TGFBIp production.
METHODS
Culture of corneal fibroblasts from normal, heterozygote
granular corneal dystrophy type II, and homozygote granular
corneal dystrophy type II patients: This study adhered to the
tenets of the Declaration of Helsinki. Keratocyte primary
cultures were prepared from corneas from the eye bank or
from heterozygote or homozygote GCD II patients after
penetrating or lamellar keratoplasty (Severance hospital IRB
approved this study-IRB-2006–0139). GCD II diagnoses
were based on the results of DNA analysis for the R124H
TGFBI mutation. Stromal explants were prepared by first
removing the epithelium and endothelium and then culturing
the explants in 10% fetal bovine serum (FBS)/Dulbecco's
Modified Eagle's medium (DMEM) at 37 °C in 5% CO2 and
in six well tissue culture plates. Corneal fibroblasts migrated
from the explants along the bottom of the plates. Cells were
confluent within 15–21 days. Cells were harvested by
enzymatic detachment using 0.05% trypsin at 37 °C for 3 min
followed by centrifugation at 1400 rpm for 5 min and
aspiration of the supernatant. The cell pellet was then
resuspended in 20 ml of the medium and cultured in 75 ml
flasks at 37 °C in 5% CO2 until confluent. Cells were then
serially trypsinized and passaged three to five times before use
in experiments. In preparation for experiments, cells were
plated at 3x103-5x103 cells per well in 96 well tissue culture
plates and incubated in 1 ml 10% FBS DMEM at 37 °C in 5%
CO2 for 24–48 h.
Time-dependent and dose-dependent effects of mitomycin C
on corneal fibroblast viability: Normal, GCD II heterozygote,
and GCD II homozygote corneal fibroblasts were incubated
with 0.02% MMC for 3, 6, and 24 h, after which cell viability
was measured using 3-[4,5-demethylthiazol-2,5-
diphenyl-2H-tetrazolium bromide] (MTT) and lactate
dehydrogenase (LDH) assays. Normal and GCD II
homozygote cells were incubated with 0%, 0.01%, 0.02%, and
0.04% MMC for 24 h after which cell viability was measured
using MTT and LDH assays. Based on the above findings,
subsequent experiments used 0.02% MMC for 6 h. Normal,
GCD II heterozygote, and GCD II homozygote cells were
incubated with 0.02% MMC for 6 h after which cell viability
was measured using LDH assays.
Lactate dehydrogenase and MTT assays: Cell viability was
determined using LDH and MTT assays. The LDH assay
(CytoTox 96R Non-Radioactive Cytotoxicity Assay;
Promega, Madison, WI) was used to evaluate cellular damage.
For the MTT assay, PBS containing 5 mg/ml MTT was added
to each well. Plates were incubated for 4 h in the absence of
light, the medium was removed, and precipitates were
resuspended in 50 µl DMSO. Absorbance at 570 nm or 540
nm was measured using a plate reader. Experiments were
performed in triplicate.
FACS analysis: The number of apoptotic cells was quantified
using propidium iodide (PI) staining and flow cytometry.
Cells (3x105-5x105 cells) were permeabilized and stained
using 5 μl annexin V-FITC and 5 μl propidium iodide (annexin
V- FITC Apoptosis Detection Kit; BioVision Inc., Mountain
View, CA). DNA staining was analyzed with FACSCalibur
(Becton-Dickinson, San Jose, CA).
Annexin V staining: Cells were stained with annexin V
(BioVision Inc.) and then incubated with an avidin-
horseradish peroxidase (HRP) complex (1:300). Binding was
visualized using a 0.05% diaminobenzidine/0.01% H2O2
solution. Cells were photographed using a fluorescence
microscope equipped with an annexin V filter.
Reverse transcriptase polymerase chain reaction analysis of
Bcl-xL, Bax, and TGFBI mRNA expression: Total cellular
RNA was isolated using SV Total RNA Isolation System
(Promega) according to the manufacturer’s instructions. The
RNA concentration and purity were determined
spectrophotometrically (Gene Quant II; Pharmacia Biotech,
Cambridge, UK). Total RNA was converted into cDNA using
a first-strand synthesis kit (Superscript; Invitrogen-Gibco,
Carlsbad, CA).
The PCR reaction for Bcl-xL involved 30 cycles of
denaturation at 94 °C for 5 min, annealing at 57 °C for 1 min,
and extension at 72 °C for 1 min followed by a final incubation
at 72 °C for 10 min. The reaction mixture contained primer
sequences specific to Bcl-xL (5′-GTA AAC TGG GGT CGC
ATT GT-3′ and 5′-TGC TGC ATT GTT CCC ATA GA-3′)
[22].
The PCR reaction for Bax involved 35 cycles of
denaturation at 95 °C for 5 min, annealing at 59 °C for 1 min,
and extension at 72 °C for 1 min followed by a final incubation
at 72 °C for 10 min. The reaction mixture contained primer
sequences specific to Bax (5′-AGA GGA TGA TTG CCG
CCG T-3′ and 5′-CAA CCA CCC TGG TCT TGG ATC-3′)
[22].
The reaction mixtures for TGFBI were incubated in a
thermal controller (Model TPC-100; MJ Research,
Watertown, MA) for 27 cycles of denaturation at 94 °C for
5 min, annealing at 55 °C for 45 sec, and extension at 72 °C
for 1 min followed by a final incubation at 72 °C for 10 min.
The reaction mixture contained primer sequences specific to
TGFBI (5′-TTG AGA GTG GTA GGG CTG CT-3′ and 5′-
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GTG TGT GCT GTG CAG AAG GT-3′) and β-actin (5′-AGC
ACT GTG TTG GCG TAC AG-3′ and 5′-GGA CTT CGA
GCA AGA GAT GG-3′).
The quantity of the amplified products was analyzed
using an image-documentation system (ImageMaster VDS;
Pharmacia Biotech Inc., Uppsala, Sweden). The reverse
transcription polymerase chain reaction (RT–PCR) products
were analyzed by electrophoresis on 1% agarose gels. β-actin
levels were used to normalize expression levels for mRNA
species assayed. The gels were photographed, and the
densities of DNA bands were quantified using a Fluor-S
MultiImager (Bio-Rad, Hercules, CA).
Immunoblot analysis for TGFBIp: Cells were washed with
ice-cold PBS and lysed with cell lysis buffer (20 mM HEPES
[pH 7.2], 10% glycerol, 10 mM Na3VO4, 50 mM NaF, 1 mM
phenylmethylsulfonyl fluoride [PMSF], 0.1 mM
dithiothreitol, 1 µg/ml leupeptin, 1 µg/ml pepstatin, and 1%
Triton X-100) on ice for 30 min. The lysate was sonicated,
and the homogenates were centrifuged at 15,000x g for 10
min. The protein concentration of the resultant supernatant
was determined using the Bradford reagent. Laemmli sample
buffer was added to samples of cell lysate protein (15 μg) or
culture media (30 μg), which were then boiled for 5 min. The
proteins were separated by SDS–PAGE (8% gels) and then
transferred to polyvinylidene fluoride (PVDF; Millipore,
Billerica, MA) membranes. Membranes were incubated with
antibodies against TGFBIp (1:1000 R&D Systems, Inc.
Minneapolis, MN) and β-actin (1:10,000 Sigma-Aldrich, St.
Louis, MO) followed by HRP-conjugated secondary
antibodies. Immunoreactive bands were visualized using an
enhanced chemiluminescence kit (ECL kit; Amersham,
Piscataway, NJ).
Statistical analysis: ANOVA was used to compare cell
viability. Statistical analysis was performed using SPSS
software (version 10.0 for Windows; SPSS Inc., Chicago, IL),
and the significance was set at p<0.05.
RESULTS
Time- dependent and dose-dependent effects of mitomycin C
on corneal fibroblast viability: With regard to the time-
dependent effects of MMC, there were fewer viable GCD II
homozygote cells than normal cells at all time points (p=0.043
at 3 h, p=0.023 at 6 h, and p=0.350 at 24 h for MTT assay;
p=0.086 at 3 h, p=0.043 at 6 h, and p<0.01 at 24 h for LDH
assay; Figure 1). While the MTT and LDH assays
demonstrated some minor differences, there were fewer viable
GCD II homozygote cells than normal cells at 6 h.
In regard to the dose-dependent effects of MMC, there
was a reduction in the number of viable GCD II homozygote
cells at all concentrations by MTT assay (p=0.028 at 3 h,
p<0.01 at 6 h, and p<0.01 at 24 h for MTT assay; p=0.034 at
3 h, p=0.065 at 6 h, and p<0.125 at 24 h for LDH assay; Figure
2). In the LDH assay, there were fewer viable GCD II
homozygote cells at 0.01% compared to normal cells. After
incubation with 0.02% MMC for 6 h, there were fewer viable
GCD II homozygote cells compared to other cell types (Figure
3).
Mitomycin C induces apoptosis: Cells were incubated with
0.02% MMC for 6 h after which they were stained and
underwent FACS analysis to determine the amount of
apoptosis and necrosis. MMC increased the proportion of
apoptotic cells particularly in GCD II homozygote cells
(Figure 4).
Cells were incubated with 0.02% MMC for 6 h after
which they were stained for annexin V to find apoptotic
changes. Cells undergoing apoptosis experienced cytoplasmic
shrinkage and perimembranous stippling. Following MMC
incubation, the GCD II homozygote cells strongly stained
positive for annexin V and displayed typical characteristics of
apoptosis while such staining was less apparent in normal cells
(Figure 5).
Expression of Bcl-xL, Bax, and TGFBI: Cells were incubated
with 0.02% MMC for 6 h after which they were harvested,
RNA was isolated, and RT–PCR analysis was performed to
Figure 1. Time course for the effect of 0.02% MMC on corneal
fibroblast viability. Corneal fibroblasts were incubated with 0.02%
MMC for various times after which cell viability was measured using
MTT and LDH assays. The MTT and LDH assays demonstrated
some minor differences, there were fewer viable GCD II homozygote
cells than normal cells. Upper panel=MTT assay, lower panel=LDH
assay. The asterisk indicates a p<0.05; ANOVA. MMC: mitomycin
C, control: without MMC, NR: normal, HE: heterozygote, HO:
homozygote.
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determine the expression levels of TGFBI and the apoptosis-
related factors, Bcl-xL and Bax. MMC reduced Bcl-xL mRNA
expression in heterozygote (p=0.045) and homozygote
(p=0.017) cells and markedly enhanced Bax expression in
GCD II homozygote cells (p<0.01). Before the application of
MMC, corneal fibroblasts expressed TGFBI mRNA at similar
levels. However, MMC treatment decreased TGFBI mRNA
expression in all three cell types. The results were statistically
significant for homozygote cells (p=0.025; Figure 6).
Cells were incubated with 0.02% MMC for 6 h after
which samples of media were taken and the cells were
harvested. Cell lysates and media were analyzed for TGFBIp
protein levels via immunoblotting. MMC reduced TGFBIp
levels in both cell lysates and media for all three cell types
(Figure 7).
DISCUSSION
MMC was first introduced as an agent that could modulate
corneal wound healing processes and reduce corneal haze
Figure 2. Concentration-dependent effect of MMC on corneal
fibroblast viability. Cells were incubated with various concentrations
of MMC for 24 h after which cell viability was measured using MTT
and LDH assays. The MTT assay demonstrated fewer viable GCD
II homozygote cells than normal cells in all concentrations. Upper
panel=MTT assay, lower panel=LDH assay. The asterisk indicates a
p<0.05; ANOVA. MMC: mitomycin C, control: without MMC, NR:
normal, HE: heterozygote, HO: homozygote.
after refractive procedures [23]. Subsequently, MMC was
used to treat recurrent subepithelial fibrosis after refractive
procedures, radial keratotomy (RK), and PRK or for
management of complications such as ‘button hole’ [24].
MMC has even been applied during the LASEK procedure in
normal corneas to improve vision after surgery [25].
However, the antiproliferative effect of this drug on
keratocytes has led investigators to fear possible long-term
keratocyte depletion and delayed wound healing [26].
We have reported that the intraoperative use of topical
0.02% MMC with PTK prevented or delayed the recurrence
of GCD II [18]. Subsequently, topical MMC was effective in
preventing the recurrence of Reis-Bücklers dystrophy after
PTK [27]. MMC has also been considered for reducing side
effects related to excessive wound healing or recurrence of
corneal dystrophy after corneal surgery [18,27,28]. Despite
the widespread clinical use of MMC, there are few in vitro
Figure 3. The effect of 0.02% MMC for 6 h on corneal fibroblast
viability. Cells were incubated with 0.02% MMC for 6 h after which
cell viability was measured using LDH assays. There were fewer
viable GCD II homozygote cells, compared to other cell types. The
asterisk indicates a p<0.05; ANOVA. MMC: mitomycin C, NR:
normal, HE: heterozygote, HO: homozygote.
Figure 4. The effect of MMC on corneal fibroblast apoptosis: FACS
analysis. Cells were incubated with 0.02% MMC for 6 h after which
they were harvested, the DNA was stained with propidium iodide,
and the cells were analyzed using FACS. MMC increased the
proportion of apoptotic cells in GCD II homozygote cells. MMC:
mitomycin C, NR: normal, HE: heterozygote, HO: homozygote.
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studies that have supported such use or few that have provided
information regarding its mechanism of action.
The present study examined the effect of MMC on
viability in normal, GCD II heterozygote, and GCD II
homozygote corneal fibroblasts. The study also sought to
determine the molecular mechanisms underlying MMC
activity. MMC reduced cell viability in a time-dependent and
dose-dependent manner in all three cell types. However, GCD
II homozygote cells were the most susceptible. FACS analysis
and annexin V staining showed that apoptosis was the cause
of cell death in all three cell types. The present data are
consistent with a previous study showing that MMC induces
keratocyte apoptosis in a time-dependent and dose-dependent
manner [29]. Also, the ratio between apoptotic and live cells
was clearly highest in GCD II homozygote cells.
Figure 5. The effect of MMC on corneal fibroblast apoptosis. Cells
were incubated with 0.02% MMC for 6 h after which they were
stained with annexin V then avidin-horseradish peroxidase (HRP)
complex (1:300), and binding was visualized using a 0.05%
diaminobenzidine/0.01% H2O2 solution. Cells were photographed
using a fluorescence microscope equipped with an annexin V filter.
Following MMC incubation, the GCD II homozygote cells showed
cytoplasmic shrinkage and perimembranous stippling prominently
compared with normal cells. MMC: mitomycin C, NR: normal, HE:
heterozygote, HO: homozygote.
The current findings suggest that GCD II homozygote
keratocytes are more susceptible to MMC-induced apoptosis
than normal keratocytes and that the application of MMC
during surgery would have a greater effect on GCD II
homozygote corneas than on normal ones. Previous studies
showed that MMC-induced keratocyte apoptosis in normal
corneas reduced the number of cells and delayed epithelial
healing but did not significantly disturb corneal anatomic
structure [30]. The decreased number and activity of
keratocytes appears to reduce corneal haze and fibrosis during
wound healing in the cornea [31]. In the present study, all three
cell types had similar levels of baseline apoptosis before the
Figure 6. The effect of MMC on Bcl-xL, Bax, and TGFBI mRNA
expression in corneal fibroblasts. Cells were incubated with 0.02%
MMC for 6 h after which RNA was isolated and subjected to RT–
PCR analysis to determine the levels of Bcl-xL, Bax, and TGFBI
mRNA expression. MMC reduced Bcl-xL mRNA expression in
heterozygote (p=0.045) and homozygote (p=0.017) cells and
markedly enhanced Bax expression in GCD II homozygote cells
(p<0.01). MMC decreased TGFBI mRNA expression statistically
significant in homozygote cells (p=0.025). The asterisk indicates a
p<0.05; ANOVA compared with normal cell. MMC: mitomycin C,
NR: normal, HE: heterozygote, HO: homozygote.
Figure 7. The effect of MMC on TGFBIp protein expression. Cells
were incubated with 0.02% MMC for 6 h after which samples of
media were taken, and the cells harvested. Cell lysates (15 μg) and
media (30 μg) were analyzed for TGFBIp protein levels using
immunoblotting. MMC reduced TGFBIp levels in both cell lysates
and media for all 3 cell types. MMC: mitomycin C, NR: normal, HE:
heterozygote, HO: homozygote.
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addition of MMC. Different levels of apoptosis were observed
in each cell type only after MMC treatment.
Bcl-xL proteins are inhibitors of the mitochondrial
apoptosis pathway. Bcl-xL proteins block the activity of their
proapoptotic counterparts including Bax, thereby preventing
the release of cytochrome c and the activation of caspase
[32,33]. Furthermore, Bcl-xL is capable of preventing cell
death, suggesting that these proteins exert independent effects
on the mitochondrial apoptotic pathway. In the present study,
the addition of MMC resulted in decreased Bcl-xL mRNA
expression in all cell types. In addition, MMC cause a marked
increase in Bax mRNA expression in GCD II homozygote
cells. MMC-induced corneal fibroblast apoptosis is associated
with the mitochondrial pathway and release of cytochrome c
[29]. These findings indicate that GCD II homozygote cells
were less able to resist MMC-induced triggering of the
mitochondrial apoptotic pathway.
The main component of corneal deposits in GCD II
patients is considered to be the mutant TGFBIp. Therefore,
TGFBI mRNA and secreted protein levels may influence the
severity of corneal deposits. Whether epithelial cells or
keratocytes are the main source of TGFBIp in TGF-β1-
induced corneal dystrophies is still under debate. Evidence of
the former includes the location of the deposits in granular
corneal dystrophy and of the initial graft recurrences in the
subepithelial region following penetrating keratoplasty (PK)
as well as the fact that the stroma is only affected later [34].
However, the present study showed that corneal fibroblasts
express TGFBI mRNA and produce TGFBIp protein that is
secreted into the media. MMC caused similar relative
reductions in TGFBI mRNA and protein levels across all three
cell types. Using in situ hybridization, a previous report
showed that TGFBI mRNA was expressed not only in the
epithelial layer but also in the stromal layer during the wound
healing process [35]. Therefore, in combination with PTK, the
inhibitory effect of MMC on TGFBI mRNA expression in
corneal fibroblasts would be a dual acting treatment for GCD
II with PTK removing pre-existing deposits and MMC
suppressing the accumulation of new deposits. However,
these effects were observed only in cell culture. Therefore,
possible differences of cell responses to MMC between cell
culture and living cornea should be considered before being
used on patients. To validate this dual effect, the clinical
application of PTK with MMC in corneal dystrophy patients
and long-term follow-up are required.
The present study found that MMC caused similar but
more extensive changes in mutated GCD II corneal fibroblasts
compared to normal cells such as the induction of apoptosis
and reduced synthesis of TGFBIp. The findings may explain
the MMC-dependent suppression or delay of recurrence in
GCD II corneas after PTK. Our previous study suggested that
this treatment only delayed recurrence in homozygote GCD
II patients. The effects of MMC in the present study were only
partial and did not completely suppress the production of
TGFBIp, which may explain the limited effect of MMC in
severe conditions such as homozygote corneas.
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